共 342 条
[1]
Balch Charles M.(2009)Final Version of 2009 AJCC Melanoma Staging and Classification Journal of Clinical Oncology 27 6199-6206
[2]
Gershenwald Jeffrey E.(2017)Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials European Journal of Cancer 82 45-55
[3]
Soong Seng-jaw(2016)Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Lancet Oncol 17 1248-1260
[4]
Thompson John F.(2018)Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study Journal of Clinical Oncology 36 391-398
[5]
Atkins Michael B.(2016)Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma European Journal of Cancer 67 46-54
[6]
Byrd David R.(2012)Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment Health and Quality of Life Outcomes 10 66-1946
[7]
Buzaid Antonio C.(2016)Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study Annals of Oncology 27 1940-91
[8]
Cochran Alistair J.(2017)Health-related quality of life results from the phase III CheckMate 067 study European Journal of Cancer 82 80-1398
[9]
Coit Daniel G.(2015)Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial Lancet Oncol 16 1389-840
[10]
Ding Shouluan(2015)Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma European Journal of Cancer 51 833-174